Tag: novartis

Crizanlizumab receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises

Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease  Sickle cell VOCs, which are triggered by multi-cell adhesion or clusters of cells that block or reduce blood flow, are associated with increased morbidity and mortality1 FDA filing of crizanlizumab anticipated in…